Menarini Group - Quality comes first

European Respiratory Society (ERS) Congress 2026

Our commitment to improving the quality of life for patients with respiratory diseases.

Marking a pivotal milestone in cardiometabolic care, the CHMP has recommended the approval of obicetrapib and the obicetrapib/ezetimibe fixed-dose combination for adults with high cholesterol.

Menarini Advances Oncology Pipeline with Second AI-Discovered Drug Deal

Reinforcing our commitment to innovation, Menarini has deepened its strategic partnership with Insilico Medicine, licensing a second novel, AI-discovered cancer drug candidate

Menarini's way of life

People are the heart of our commitment

EMA starts review of Menarini’s new cholesterol treatments

On 2 September 2025, the European Medicines Agency began reviewing Menarini’s applications for two potential treatments to help lower high cholesterol in adults .

Oncology

Committed to make a difference in Cancer Patients' Lives

In Menarini Group

Quality comes first